SCHEMBL3532899

SCHEMBL3532899

CC(C)COC(=O)N1CCN(c2cncc(-c3ccccc3O)n2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.47
GAA P10253 2/20 0.47
MAPT P10636 4/20 0.42
KDM4E B2RXH2 4/20 0.41
POLB P06746 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPK1 P28482 2/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
SMARCA2 P51531 1/20 0.40
SMARCA4 P51532 1/20 0.40
PBRM1 Q86U86 1/20 0.40
LMNA P02545 4/20 0.40
HPGD P15428 1/20 0.40
RET P07949 1/20 0.40
TSHR P16473 4/20 0.39
HSD17B10 Q99714 2/20 0.39
SMO Q99835 1/20 0.39
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12991231 0.90 ALDH1A1 (0.41) SMN1; SMN2GAAMAPTKDM4EPOLB
SCHEMBL12991312 0.88 ITGB2 (0.40) SMN1; SMN2GAAMAPTKDM4EPOLB
SCHEMBL13439444 0.87 GAA (0.46) SMN1; SMN2GAAMAPTKDM4EPOLB
SCHEMBL3532952 0.81 DRD2 (0.43) MAPTKDM4ETSHRSMOALDH1A1
SCHEMBL3532352 0.81 ITGB2 (0.47) SMN1; SMN2GAASMARCA2SMARCA4PBRM1
SCHEMBL12781798 0.81 SMN1; SMN2 (0.53) SMN1; SMN2GAAMAPTKDM4EMEN1
SCHEMBL12991345 0.81 TSHR (0.40) SMN1; SMN2GAAKDM4EMAPK1LMNA
SCHEMBL3527295 0.81 TSHR (0.40) SMN1; SMN2GAAKDM4EMAPK1LMNA
SCHEMBL3554874 0.80 GAA (0.44) SMN1; SMN2GAAMAPTKDM4ESMARCA2
SCHEMBL12991337 0.80 ALDH1A1 (0.45) SMN1; SMN2GAAMAPTKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7858786-B2 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCOROPATED (US) 2010-12-28 US disclosed
US-7858786-B2 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCOROPATED (US) 2010-12-28 US disclosed
US-7858786-B2 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCOROPATED (US) 2010-12-28 US disclosed
EP-1877385-A1 PYRIMIDINES AND PYRAZINES USEFUL AS MODULATORS OF ION CHANNELS Vertex Pharmaceuticals Incorporated (US) 2008-01-16 EP disclosed
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-04-26 US disclosed
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-04-26 US disclosed
WO-2006119451-A1 PYRIMIDINES AND PYRAZINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels KCNJ1, KCNJ2, KCNJ11 SMN1; SMN2 1173/4885GAA 3580/4885MAPT 2601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.